Novartis Pharmaceuticals Achieves Dismissal of Bisphosphonate Claims

Novartis Pharmaceuticals received a voluntary dismissal of claims from plaintiffs for their bisphosphonate drug in the midst of a trial. Novartis manufactures and sells Zometa, a drug indicated to strengthen bone in cancer patients whose disease has metastasized to bone.

Faegre Baker Daniels served as lead trial counsel in the case. This was one of hundreds of similar cases against Novartis ongoing across the country. Brown v. Novartis Pharmaceuticals Corp., No. 7:08-cv-00130-FL (E.D. NC 2012)

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。